Revance Therapeutics to Release First Quarter 2015 Financial Results Wednesday, May 13, 2015
April 29, 2015 16:02 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook
March 02, 2015 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Appoints Dr. Philip Vickers to Its Board of Directors
February 26, 2015 17:00 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference
February 17, 2015 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen and Company 35th Annual Health...
Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
February 12, 2015 16:06 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015
January 12, 2015 07:00 ET
|
Revance Therapeutics, Inc
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications
Updates 2014 Financial Guidance
NEWARK, Calif., Jan....
Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study
January 08, 2015 16:05 ET
|
Revance Therapeutics, Inc
RT002 Achieved Median Duration of 7 Months
Phase 2 Active Comparator Study Underway
NEWARK, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty...
Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002
January 05, 2015 07:00 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics Added to NASDAQ Biotechnology Index
December 18, 2014 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and...
Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
November 20, 2014 19:20 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...